Globus Medical, Inc. GMED
86.75 USD +7.17 (+9.01%)
Nov 4, 2026, 12:22 PM EST
80.91 Day range 86.79
60.26 52-week range 101.40
- YTD
- -0.64%
- 1 year
- +40.69%
News
benzinga.com Globus Medical Acquires Synaptive Medical; Financial Terms Not Disclosed Globus Medical, Inc. a leading musculoskeletal technology company, today announced that it completed the acquisition of Synaptive Medical, deepening the Company's presence in cranial neurosurgery and…
seekingalpha.com Globus Medical: The Shrinking Robot Line Hides A Growing Annuity Globus Medical is leveraging flexible leasing models to expand its installed base, prioritizing recurring high-margin implant sales over upfront capital revenue. GMED's post-NuVasive integration is…
zacks.com GMED vs. AXGN: Which Stock Should Value Investors Buy Now? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and AxoGen (AXGN). But which of these two companies is the best option for…
zacks.com Wall Street Analysts Think Globus Medical (GMED) Could Surge 30.52%: Read This Before Placing a Bet The consensus price target hints at a 30.5% upside potential for Globus Medical (GMED). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…
zacks.com Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com 2 Healthcare Technology Stocks for a Digital Health Boom GMED and STE offer exposure to healthcare technology growth, with projected 2026 EPS gains, attractive valuations and innovations in essential medical services.
defenseworld.net Gibbs Wealth Management Purchases 7,829 Shares of Globus Medical, Inc. $GMED Gibbs Wealth Management purchased a new position in shares of Globus Medical, Inc. (NYSE: GMED) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund…
prnewswire.com Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Globus Medical, Inc. (NYSE: GMED) breached their…
zacks.com Globus Medical (GMED) is a Top-Ranked Value Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com GMED or AXGN: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better…
globenewswire.com Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026 AUDUBON, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will highlight its latest spine innovations at the…
globenewswire.com Globus Medical Schedules Third Quarter Earnings Release and Conference Call AUDUBON, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended…
benzinga.com Globus Medical Q2 2026 Earnings Call Transcript On Thursday, Globus Medical (NYSE:GMED) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
zacks.com Reasons to Add Globus Medical Stock to Your Portfolio Now GMED gains musculoskeletal share on strong spine and trauma growth, while product innovation and a debt-free balance sheet support its appeal.
zacks.com Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific Globus Medical, Intuitive Surgical and Thermo Fisher Scientific have been highlighted in this Industry Outlook article.
zacks.com Here's Why Globus Medical (GMED) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com 3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes GenAI offers growth opportunities for GMED, ISRG and TMO, but evolving regulations and industry risks are likely to shape adoption.
benzinga.com RBC Capital Maintains Outperform on Globus Medical, Lowers Price Target to $85 RBC Capital analyst Kendall Au maintains Globus Medical (NYSE:GMED) with a Outperform and lowers the price target from $115 to $85.
zacks.com GMED vs. ITGR: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks offers value investors a better bang for their…
etftrends.com The Top HealthTech Questions Landing on Our Desks Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled…
zacks.com What Makes Globus Medical (GMED) a New Strong Buy Stock Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com Top Robotics Stocks to Add to Your Portfolio for Impressive Returns Robotics is poised for robust long-term growth. Consider NVDA, TER, ZBRA and GMED for potential market dominance across sectors.
zacks.com GMED vs. ITGR: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Integer (ITGR). But which of these two companies is the best option for those looking…
benzinga.com Globus Medical Receives CE Mark For Its Excelsius3D Imaging System For Commercial Sale In EU, U.K. Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced that the Excelsius3D™ intelligent 3-in-1 imaging system is now CE marked for commercial sale in the…
benzinga.com Globus Medical To Acquire Higgs Boson Health; Financial Terms Not Disclosed Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, today announced the acquisition of Higgs Boson Health, a digital healthcare experience company based in Durham, NC and…
benzinga.com Wells Fargo Maintains Overweight on Globus Medical, Lowers Price Target to $99 Wells Fargo analyst Larry Biegelsen maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $103 to $99.
benzinga.com Globus Medical Raises FY2026 Adj EPS Guidance from $4.70-$4.80 to $4.95-$5.05 vs $4.74 Est; Affirms FY2026 Sales Guidance of $3.180B-$3.220B vs $3.201B Est Globus Medical (NYSE:GMED) raises FY2026 Adj EPS guidance from $4.70-$4.80 to $4.95-$5.05 vs $4.74 analyst estimate. Affirms FY2026 sales outlook from $3.180 billion-$3.220 billion to $3.180…
benzinga.com Globus Medical Q2 Adj. EPS $1.34 Beats $1.10 Estimate, Sales $789.612M Beat $782.840M Estimate Globus Medical (NYSE:GMED) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.10 by 21.82 percent. This is a 55.81 percent increase over earnings of $0.86…- benzinga.com Truist Securities Maintains Buy on Globus Medical, Lowers Price Target to $100 Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $115 to $100.
- benzinga.com RBC Capital Maintains Outperform on Globus Medical, Lowers Price Target to $115 RBC Capital analyst Shagun Singh maintains Globus Medical (NYSE:GMED) with a Outperform and lowers the price target from $120 to $115.
- benzinga.com BMO Capital Initiates Coverage On Globus Medical with Outperform Rating, Announces Price Target of $94 BMO Capital initiates coverage on Globus Medical (NYSE:GMED) with a Outperform rating and announces Price Target of $94.
- benzinga.com Stifel Maintains Hold on Globus Medical, Lowers Price Target to $80 Stifel analyst Tom Stephan maintains Globus Medical (NYSE:GMED) with a Hold and lowers the price target from $95 to $80.
benzinga.com AI Chips Power Wall Street Higher, Dow Eyes Records: Stock Market Today Tech and semis lead the S&P 500 and Nasdaq higher into quarter-end
benzinga.com Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts changed their outlook on top names. See all rating changes on our analyst ratings page. Barclays, Wells Fargo, Piper Sandler, Leerink Partners, Truist Securities, and…- benzinga.com Piper Sandler Maintains Overweight on Globus Medical, Lowers Price Target to $100 Piper Sandler analyst Matt O'Brien maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $115 to $100.
benzinga.com Jim Cramer Flags Industrial Company With 'Almost No Revenue,' Says No To Rocket Companies Cramer says Rocket Companies is a "play" on the idea that new Fed Chair Kevin Warsh will cut interest rates, and that's a long shot.- benzinga.com RBC Capital Maintains Outperform on Globus Medical, Raises Price Target to $120 RBC Capital analyst Shagun Singh maintains Globus Medical (NYSE:GMED) with a Outperform and raises the price target from $115 to $120.
benzinga.com Wells Fargo Maintains Overweight on Globus Medical, Lowers Price Target to $103 Wells Fargo analyst Larry Biegelsen maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $104 to $103.- benzinga.com Needham Maintains Buy on Globus Medical, Raises Price Target to $117 Needham analyst David Saxon maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $114 to $117.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Globus Medical Raises FY2026 Adj EPS Guidance from $4.40-$4.50 to $4.70-$4.80 vs $4.47 Est; Affirms FY2026 Sales Guidance of $3.180B-$3.220B vs $3.202B Est Globus Medical (NYSE:GMED) raises FY2026 Adj EPS guidance from $4.40-$4.50 to $4.70-$4.80 vs $4.47 analyst estimate. Affirms FY2026 sales outlook from $3.180 billion-$3.220 billion to $3.180…
- benzinga.com Globus Medical Q1 Adj. EPS $1.12 Beats $0.92 Estimate, Sales $759.854M Beat $736.999M Estimate Globus Medical (NYSE:GMED) reported quarterly earnings of $1.12 per share which beat the analyst consensus estimate of $0.92 by 21.74 percent. This is a 64.71 percent increase over earnings of $0.68…
- benzinga.com Wells Fargo Maintains Overweight on Globus Medical, Raises Price Target to $104 Wells Fargo analyst Vik Chopra maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $98 to $104.
- benzinga.com Barclays Maintains Overweight on Globus Medical, Raises Price Target to $123 Barclays analyst Matt Miksic maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $118 to $123.
benzinga.com 8 Analysts Assess Globus Medical: What You Need To Know - benzinga.com Needham Maintains Buy on Globus Medical, Raises Price Target to $114 Needham analyst David Saxon maintains Globus Medical (NYSE:GMED) with a Buy and raises the price target from $112 to $114.
benzinga.com Earnings Scheduled For February 24, 2026 
benzinga.com The Analyst Verdict: Globus Medical In The Eyes Of 13 Experts 
benzinga.com This Southwest Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday - benzinga.com Needham Upgrades Globus Medical to Buy, Announces $112 Price Target Needham analyst David Saxon upgrades Globus Medical (NYSE:GMED) from Hold to Buy and announces $112 price target.